Search results for "cancer chemotherapy"

showing 10 items of 12 documents

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study

2019

BackgroundEribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy.MethodsPatients with primary triple negative breast cancer ≥2 cm received doxorubicin 60 mg/m2 and paclitaxel 200 mg/m2 x 4 cycles (AT) followed by E 1.4 mg/m2 x 4 cycles. Primary endpoint was pathological complete response (pCR) rate; secondary and explorative endpoints included clinical/metabolic response rates and safety, and biomarker analysis, respectively. Using a two-stage Simon design, 43 patients were to be included provided that 4 of 13 patients had achieved pCR in the…

0301 basic medicineOncologyCancer TreatmentTriple Negative Breast NeoplasmsImmunostainingToxicologyPathology and Laboratory MedicineBiochemistryMetastasis0302 clinical medicineBreast TumorsClinical endpointMedicine and Health Sciencesmetastatic breast cancer Eribulin mesylate epithelial–mesenchymal transition.AnthracyclinesTriple-negative breast cancerStainingMultidisciplinaryPharmaceuticsQRKetonesMetastatic breast cancerNeoadjuvant TherapyTreatment OutcomeSurgical OncologyOncology030220 oncology & carcinogenesisMedicineFemaleTaxoidsResearch ArticleAdultBridged-Ring CompoundsClinical Oncologymedicine.medical_specialtyAnthracyclineScienceSurgical and Invasive Medical ProceduresNeutropeniaResearch and Analysis Methods03 medical and health sciencesCancer ChemotherapyBreast cancerbreast cancerDrug TherapyInternal medicinemedicineHumansChemotherapyFuransTaxaneToxicitybusiness.industryCancers and NeoplasmsBiology and Life Sciencesmedicine.disease030104 developmental biologySpecimen Preparation and TreatmentMED/06 - ONCOLOGIA MEDICAClinical MedicinebusinessBiomarkers
researchProduct

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

2019

BackgroundIn this study based on the BRENDA data, we investigated the impact of endocrine ± chemotherapy for luminal A, nodal positive breast cancer on recurrence free (RFS) and overall survival (OS). In addition, we analysed if tumor size of luminal A breast cancer influences survival in patients with the same number of positive lymph nodes.MethodsIn this retrospective multi-centre cohort study data of 1376 nodal-positive patients with primary diagnosis of luminal A breast cancer during 2001-2008 were analysed. The results were stratified by therapy and adjusted by age, tumor size and number of affected lymph nodes.ResultsIn our study population, patients had a good to excellent prognosis …

0301 basic medicineOncologyDose-dense chemotherapyAdjuvant Chemotherapymedicine.medical_treatmentCancer Treatment0302 clinical medicineBreast TumorsMedicine and Health SciencesEndocrine TumorsMultidisciplinaryPharmaceuticsQREndocrine TherapyMiddle AgedPrognosisSurvival RateOncologyDocetaxelChemotherapy AdjuvantLymphatic Metastasis030220 oncology & carcinogenesisMedicineFemaleLymphAnatomyResearch Articlemedicine.drugClinical Oncologymedicine.medical_specialtyScienceBreast NeoplasmsDisease-Free SurvivalLymphatic SystemCancer Chemotherapy03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancermedicineHumansChemotherapyEndocrine systemSurvival rateAgedRetrospective StudiesChemotherapybusiness.industryBiology and Life SciencesCancers and NeoplasmsRetrospective cohort studymedicine.disease030104 developmental biologyLymph NodesClinical MedicinebusinessPLoS ONE
researchProduct

DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.

2019

Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, …

AntifungalCancer chemotherapymedicine.drug_classDrug Evaluation Preclinicaldihydrofolate reductase (DHFR) enzymePharmaceutical ScienceAntineoplastic AgentsComputational biologyReview01 natural scienceshybrid compoundsAnalytical Chemistrylcsh:QD241-44103 medical and health sciencesStructure-Activity RelationshipFolic Acidlcsh:Organic chemistryheterocyclic compoundsNeoplasmsDihydrofolate reductaseparasitic diseasesDrug DiscoverymedicineAnimalsHumansPhysical and Theoretical Chemistry030304 developmental biology0303 health sciencesHeterocyclic compoundbiology010405 organic chemistryDrug discoveryOrganic ChemistryDHFR inhibitors as anticancer agentSettore CHIM/08 - Chimica Farmaceutica0104 chemical sciencesDHFR drug discoveryTetrahydrofolate DehydrogenaseMechanism of actionChemistry (miscellaneous)Settore CHIM/03 - Chimica Generale E InorganicaDHFR inhibitors as anticancer agentsbiology.proteinMolecular MedicineFolic Acid Antagonistsmedicine.symptomMolecules (Basel, Switzerland)
researchProduct

Targeting cancer with peptide aptamers

2011

Renaud Seigneuric 1,2 , Jessica Gobbo 1,2 , Pierre Colas 3 , Carmen Garrido 1,2 1 Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France 2 Universite de Bourgogne, Dijon, France 3 CNRS USR 3151, P2I2 Group, Station Biologique, Roscoff, Bretagne, France Received: June 22, 2011; Accepted: June 24, 2011; Published: June 24, 2011; Correspondence: Renaud Seigneuric, email: // // Abstract A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but al…

Cancer chemotherapyAptamermedicine.medical_treatmentRecombinant Fusion ProteinsPeptide Aptamersheat shock proteinAntineoplastic AgentsComputational biologyPharmacologyBiologyTargeted therapy03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansNanotechnologyMolecular Targeted TherapyHeat-Shock Proteins030304 developmental biologyCancer0303 health sciencesClinical Trials as TopicCanceraptamerAntineoplastic Protocolsmedicine.diseasetargeted therapypeptide3. Good healthOncology030220 oncology & carcinogenesisResearch PerspectivesAptamers PeptideOncotarget
researchProduct

From traditional Chinese medicine to rational cancer therapy

2007

Many natural products and derivatives thereof belong to the standard repertoire of cancer chemotherapy. Examples are Vinca alkaloids, taxanes and camptothecins. In recent years, the potential of natural products from plants, notably from medicinal plants used in traditional Chinese medicine (TCM), has been recognized by the scientific community in the Western world. To provide an example of the most recent developments in this field, we have selected several compounds, namely artesunate, homoharringtonine, arsenic trioxide and cantharidin, that are found in natural TCM products and that have the potential for use in cancer therapy. Controlled clinical studies have shown that homoharringtoni…

Cancer chemotherapyVincaPharmacognosyCancer therapyTraditional Chinese medicinechemistry.chemical_compoundNeoplasmsmedicineAnimalsHumansMedicine Chinese TraditionalArsenic trioxideMedicinal plantsMolecular BiologyTraditional medicinebiologybusiness.industryCancermedicine.diseasebiology.organism_classificationAntineoplastic Agents PhytogenicchemistryHomoharringtonineWestern WorldMolecular MedicinebusinessTrends in Molecular Medicine
researchProduct

Smart copolymer coated SPIONs for colon cancer chemotherapy

2019

Human colon cancer is one of the higher aggressive solid tumors, whose high mortality, much like many other solid tumors, results from metastasis formation. To reduce this high mortality, more effective chemotherapy, allowing a specific tumor accumulation and an efficient early-stage medical imaging as well, are still needed. At this regard, stimuli-responsive nanocarriers for anticancer drug delivery are promising strategy in cancer therapy. For this purpose, a dual targeted redox-responsive drug delivery system, prepared by coating superparamagnetic nanoparticles (SPIONs) with the amphiphilic copolymer INU-LA-PEG-FA and loading doxorubicin (DOXO-SPIONs) was investigated as tool for solid …

Male3003Colorectal cancerPolymersmedicine.medical_treatmentPharmaceutical ScienceMice Nude02 engineering and technologyDual targeting030226 pharmacology & pharmacyPolyethylene Glycols03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineDrug Delivery SystemsFolic AcidmedicineAnimalsHumansDoxorubicinReceptorMagnetite NanoparticlesRedox-responsiveChemotherapyAntibiotics Antineoplasticmedicine.diagnostic_testThioctic AcidInulinSPIONMagnetic resonance imaging021001 nanoscience & nanotechnologymedicine.diseaseMagnetic Resonance ImagingXenograft Model Antitumor AssaysUp-RegulationLipoic acidchemistryDoxorubicinSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryColonic NeoplasmsCancer researchCancer chemotherapyNanocarriers0210 nano-technologyOxidation-Reductionmedicine.drugMRI
researchProduct

Unraveling the interaction between doxorubicin and DNA origami nanostructures for customizable chemotherapeutic drug release

2020

Doxorubicin (DOX) is a commonly employed drug in cancer chemotherapy, and its high DNA-binding affinity can be harnessed in preparing programmable DOX-loaded DNA nanostructures that can be further tailored for targeted delivery and therapeutics. Although DOX has been widely studied, the existing literature of promising DOX-loaded DNA nanocarriers remains limited and incoherent. A number of reports have over-looked the fundamentals of the DOX-DNA interaction, let alone the peculiarities arising from the complexity of the system as a whole. Here, based on an in-depth spectroscopic analysis, we characterize and optimize the DOX loading into different 2D and 3D scaffolded DNA origami nanostruct…

NanostructureCancer chemotherapytechnology industry and agriculturemacromolecular substancescarbohydrates (lipids)chemistry.chemical_compoundchemistryDrug deliverypolycyclic compoundsmedicineBiophysicsDNA origamiDoxorubicinChemotherapeutic drugsNanocarriersDNAmedicine.drug
researchProduct

Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits.

1976

The permeability of the bladder mucosa to thiotepa and to the anthraquinonic antibiotics, adriamycin and daunomycin, was investigated both in humans and in experimental animals. Instillations in rabbits were performed either in intact males or in animals with ligated ureters. Absorption of thiotepa was significantly higher than that of the antibiotics both in men and in rabbits. Furthermore, a qualitative difference was observed in rabbits in relation to time and with regard to fixation to vesical tissues. In man, absorption was highest after transurethral surgery. It was also increased in cases with extensive anaplastic tumours or in the presence of acute inflammatory reactions.

NephrologyMalemedicine.medical_specialtyCancer chemotherapymedicine.drug_classUrologyAntibioticsUrinary BladderUrologyThioTEPAPharmacologyPermeabilityTransurethral surgeryInternal medicinemedicineAnimalsHumansQualitative differenceMucous MembraneChemistryBladder MucosaDaunorubicinDoxorubicinRabbitsThiotepamedicine.drugUrological research
researchProduct

Between Scylla and Charibdis: eIF2α kinases as targets for cancer chemotherapy

2011

[EN] The eIF2 alpha kinases integrate translation initiation rates with nutrient availability, thus allowing cells to adapt to nutrient scarcity. Recent evidence has uncovered new functions of these kinases in tumour cell biology, ranging from regulation of cell cycle progression, maintenance of genome stability, control of apoptosis, and cell survival under nutrient stress and hypoxia. Accordingly, active eIF2 alpha kinases modulate the antineoplasic activity of several antitumour drugs, either by exacerbating their cytotoxic effect or by promoting chemoresistance. Understanding of eIF2 alpha kinases molecular roles may provide mechanistic insights into how tumour cells sense and adapt to …

PERKBioquímicaTranslationBiologiaCancer ResearchCancer chemotherapyEukaryotic Initiation Factor-2Antineoplastic AgentsBiologyBioinformaticsNeoplasmsBIOQUIMICA Y BIOLOGIA MOLECULARHumansCytotoxic T cellCell survivalGenome stabilityKinaseNutrient stressPKRGeneral MedicineProtein kinase ROncologyApoptosiseIF2 alpha phosphorylationCancer researchGCN2Clinical and Translational Oncology
researchProduct

Antimicrobial and antiproliferative activity of Athamanta sicula L. (Apiaceae).

2010

Background: Athamanta sicula L., a member of Apiaceae, is an annual perennial herb and it is known in Sicilian popular medicine with the name of “spaccapietre” (rock splitters), because fresh roots infusions are indicated as diuretic and used in the treatment of diseases of the urinary tract, and to dissolve kidney stones. Materials and Methods: Acetone extracts of leaves, flowers, and stems of A. sicula L. were investigated in vitro for antibacterial and cytotoxic activities. Antimicrobial activity was carried out against bacterial and fungal strains and antiproliferative activity against a group of human cancer cell lines (K-562, NCI-H460, and MCF-7). Results: All acetone extracts, apiol …

antiproliferative activityApiaceaeCancer chemotherapyTraditional medicineApiolPharmaceutical ScienceBiologyAntimicrobial activitySettore BIO/19 - Microbiologia GeneraleAntimicrobialbiology.organism_classificationIn vitroMyristicinchemistry.chemical_compoundAthamanta siculamyristicinAntimicrobial activity antiproliferative activity Athamanta sicula apiol myristicinchemistryCell cultureDrug DiscoveryBotanyapiolOriginal ArticleAthamanta siculaPharmacognosy magazine
researchProduct